in animals, the authors' findings suggest that many combinations of DNAJs might interact, to make complexes that untangle specific clients.
Nillegoda and colleagues' data are restricted to tests on heat-induced protein aggregates, but it will be important to examine if and how DNAJ-Hsp70 complexes act on the various types of aggregate that cause human degenerative disorders 2 . In such diseases, only chaperones that inhibit the formation of aggregates have been described so far 11 . Inhibition of aggregation might delay the onset of disease, but would require a continual treatment that begins before the disease arises -an unfeasible strategy for diseases of spontaneous or unknown origin. By contrast, targeting disaggregation activity after the first symptoms of disease become apparent could be of therapeutic value. It will be necessary to determine the stage in vivo at which the DNAJ-Hsp70 complex acts to untangle aggregates brought about by different disease-associated proteins; to define the different DNAJ combinations involved; and to test whether the complex can alleviate aggregation-associated toxicity and thus halt disease progression. ■ Harm H. Kampinga homo dimer. One protein from each homodimer engages in this interaction, and the other is free to interact with an Hsp70 molecule. Thus, two Hsp70 molecules can be recruited to each complex.
The authors suggest that the hydrolysis of ATP molecules by Hsp70 brings about entropic pulling, a process that untangles polypeptide molecules from the aggregate, allowing them to be refolded or degraded (Fig. 1) . Finally, Nillegoda et al. demonstrate that the complex works most efficiently when the preformed aggregates have been generated in the presence of small Hsps. These proteins are excellent ATP-independent chaperones, and can join strings of protein monomers under conditions of acute stress, incorporating these unfolded proteins into an aggregate -a process that makes the aggregates themselves more accessible for disaggregation reactions 8 . A basic question that remains to be resolved is why animals lost Hsp104 and evolved to use DNAJs for disaggregation instead. One speculation is that Hsp104 is rather promiscuousit will efficiently break down any aggregated protein complex. In animal cells, this would include complexes that are necessary for cellular function, such as RNA granules, which are assembled by controlled aggregation and are needed to transport RNA along neurons 9 . By contrast, the complex discovered in this study seems to allow controlled, substrate-specific disaggregation.
The existence of an animal disaggregating complex provides an explanation for previously observed protein-disaggregation activity in mammals 4 . Furthermore, the complex acts in a similar way to the specialized DNAJ-Hsp70 combinations that disassemble normal, non-pathological protein complexes (for example, interactions between Hsp70 and the DNAJ auxilin mediate the removal of clathrin protein from certain vesicles 10 ). Given the large number of DNAJ proteins 6 investigated the mechanism underlying protein disaggregation in animals. They report that two classes of DNAJ protein, DNAJA and DNAJB, acting as homodimers, use their carboxy-terminal domains (CTDs) to bind to aggregates. One molecule of the DNAJA homodimer binds to CTD1 of the adjacent DNAJB through a J-domain, and vice versa. The other subunit of each homodimer uses its J-domain to bind to one Hsp70 molecule, recruiting Hsp70 to bind to the aggregate. Entropic pulling forces, driven by Hsp70 binding to and hydrolysing ATP molecules, untangle a polypeptide molecule from the aggregate. The released polypeptide can then be folded into a normal protein. The DNAJ-Hsp70 complex breaks apart, and the process begins again.
LONGEVITY

Mapping the path to a longer life
Inhibiting the PI3K branch of the cell signalling induced by insulin and insulinlike growth factor can extend lifespan. The finding that inhibiting the RAS branch also extends lifespan in flies suggests a new target for anti-ageing drugs.
M O R R I S F. W H I T E
U nderstanding how cellular nutrientsensing and homeostasis affect an organism's lifespan and susceptibility to cancer and degenerative diseases is clinically important but scientifically difficult. Work in model organisms, first in nematode worms 1 and then in fruit flies 2 , has established that increasing the activity of the transcription factor FOXO, by reducing insulin and insulinlike growth factor signalling (IIS), can protect against cellular damage and ageing. Writing in Cell, Slack et al. 3 now show that selective mutation of the fruit fly IIS adaptor protein Chico to disrupt either of the two major IIS pathways -the RAS-ERK or the PI3K-AKT cascades -can extend the flies' lifespan. They find that inhibiting ERK signalling activates the transcriptional-repressor protein AOP, which, surprisingly, extends lifespan by just as much as the activation of FOXO that occurs during PI3K inhibition. This finding may have uncovered a new target for extending lifespan that lacks the adverse effects associated with PI3K inhibition, which include dysregulated metabolism, reduced growth and infertility. From a clinical perspective, a reduced IIS pathway. Trametinib inhibits the ERK branch of the IIS pathway by inhibiting the protein kinase enzyme MEK (Fig. 1) . The authors also show that the extension of fly lifespan by ERK or PI3K inhibition is not additive, which suggests that the two branches of the pathway might converge on modulating the expression of common genes that regulate lifespan 10 . Inhibition of ERK activates AOP, whereas inhibition of PI3K activates FOXO; both transcription factors do indeed bind a common subset of genes, but the exact targets that control lifespan are unknown 10 ( Fig. 1) . Moreover, FOXO is usually a transcriptional activator, whereas AOP is a repressor that opposes the activity of another factor, PNT, in Drosophila. Interestingly, coactivation of FOXO and PNT can have detrimental effects that are attenuated by AOP 10 , indicating that favourable crosstalk between AOP and FOXO might modulate common genes needed to extend lifespan.
Despite the potential to bypass PI3K inhibition, it remains to be investigated whether inhibiting the ERK cascade can extend mammalian lifespan without any adverse effects. ERK is a member of the MAPK enzyme family, which mediates cellular responses to a wide range of extracellular cues to regulate cell growth, differentiation and survival. Although MEK inhibition has been shown 11 to improve glucose tolerance in diet-induced obese mice, the tissues in which this is beneficial are ill defined. Further work is needed to establish whether inhibiting the ERK signalling branch is a plausible mechanism-based strategy for extending lifespan, especially when started in adults.
While work continues to devise medical strategies to extend lifespan, calorie restriction remains the best-known way to increase lifespan in yeast, nematodes, fruit flies, rodents and some primates 12 . Calorie restriction can reduce the progression of age-related diseases, including obesity, insulin resistance, type 2 diabetes, cardiovascular disease and cancer, but it is difficult for people to use in the long term and can be dangerous if unmonitored or used to excess; furthermore, its beneficial effects on human lifespan are unproven 13 . Recent work suggests that a fasting-mimicking diet that produces intermittent, brief bouts of calorie restriction can produce health benefits in people and extend the lifespan of mice 14 . Both these approaches increase insulin sensitivity and reduce circulating insulin and IGF1 concentrations, and so reduced IIS might be involved in the observed effects. Whether medical strategies -such as using the drug rapamycin to inhibit the enzyme TOR 15 , the antidiabetic drug acarbose to mimic calorie restriction 16 , or inhibiting the ERK cascade as described by Slack and colleagues -can exploit or augment the underlying molecular mechanisms engaged by calorie restriction and reduced IIS in the face of nutrient excess is an important area for future investigation. ■ pathway that extends lifespan is different from the resistance to the hormone insulin that leads to metabolic syndrome -the medical term for a combination of diabetes, high blood pressure and obesity. The most frequent misconception is that increasing the amount of circulating insulin to overcome insulin resistance is a healthy goal. Although increasing circulating insulin levels can prevent high blood glucose levels and slow the progression to type 2 diabetes, it is associated with obesity and abnormal lipid levels and cardiovascular disease. Moreover, at the cellular level, chronic high insulin or long-term insulin therapy can retard tissue repair and maintenance by inhibiting autophagy, the process that removes damaged intracellular proteins. How to safely achieve a longer lifespan by reducing IIS in the face of high-sugar diets that promote insulin resistance and increase insulin levels is a challenging conundrum.
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The fruit fly Drosophila melanogaster is useful for investigating the relationship between the IIS pathway and lifespan because it has a short life cycle and its genome encodes single copies of many IIS components. However, translating discoveries in fruit flies to other organisms can be tricky, because in people and other animals the IIS pathway is distributed between two homologous receptors (InsR and IGF1R), three or four adaptor proteins (IRS1, IRS2, IRS3 in rodents, and IRS4) and several effector proteins of the MAPK, PI3K, ATK and FOXO families. Some variants in the genes encoding IGF1R 4 and FOXO3A 5 have been associated with human longevity; however, complete loss of InsR or IGF1R function is fatal after birth for mice and people. Yet inactivation of InsR in murine adipose tissue extends lifespan 6 , as does deletion of IGF1R in the brain 7 . Thus the window for increasing lifespan by modulating IIS in mammals seems to be tissue specific.
The natural loss of growth-hormone receptors in humans with Laron syndrome (a type of dwarfism) causes obesity and reduces circulating insulin and IGF1, as well as decreasing the incidence of diabetes or cancer 8 . Notably, mice without growthhormone receptors share similar traits and are the longest-lived laboratory mouse strain. Clearly, it is essential to understand the tissue-specific effects of reduced IIS in mammals to modulate lifespan with the fewest possible adverse effects.
A major problem with reduced IIS is the risk of dysregulated metabolism and growth associated with inhibiting the PI3K cascade 9 . Despite this, efforts to target the PI3K branch of IIS in ageing might be successful with a better understanding of which protein isoforms to target and with improved inhibitors. In the meantime, Slack et al. find that exposing flies to the small molecule trametinib, currently used for cancer therapy, achieves similar lifespan extension to the inhibition of the PI3K 
